Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | terminated | Phase 1 | 21 | Prelude TherapeuticsINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)(VOYAGE) | terminated | Phase 1 / Phase 2 | 244 | MacroGenicsINDUSTRY | 8 | Jan 30, 2024 | clinicaltrials |
| NCT04092179 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | terminated | Phase 1 / Phase 2 | 27 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04196010 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms | terminated | Phase 1 | 13 | University of WashingtonOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05066165 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Intellia TherapeuticsINDUSTRY | 2 | Dec 28, 2023 | clinicaltrials |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | terminated | Phase 1 / Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03904251 | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02520011 | Alvocidib Biomarker-driven Phase 2 AML Study | terminated | Phase 2 | 104 | Sumitomo Pharma America, Inc.INDUSTRY | 4 | Nov 15, 2023 | clinicaltrials |
| NCT03969420 | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | terminated | Phase 2 | 11 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 72 | Fate TherapeuticsINDUSTRY | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03690154 | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | terminated | Phase 1 | 67 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 2 | Oct 13, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04166929 | Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS(Bigeminy) | terminated | Phase 2 | 6 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS(THRIVE) | terminated | Phase 2 / Phase 3 | 1 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03067571 | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 42 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | terminated | Phase 1 | 8 | Biotheryx, Inc.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04002115 | Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML | terminated | Phase 2 | 2 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | terminated | Phase 1 / Phase 2 | 8 | H Scott BoswellOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) | terminated | Early Phase 1 | 46 | AmgenINDUSTRY | 3 | Sep 1, 2023 | clinicaltrials |
| NCT05501171 | Psychological Mobile App for Patients With AML | terminated | N/A | 11 | Massachusetts General HospitalOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02134782 | Yoga Fatigue Study | terminated | N/A | 125 | The Hospital for Sick ChildrenOTHER | 2 | Aug 1, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04679194 | Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT | terminated | Phase 1 | 11 | Mana TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02882321 | Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Y-mAbs TherapeuticsINDUSTRY | 1 | May 30, 2023 | clinicaltrials |
| NCT02203773 | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 212 | AbbVieINDUSTRY | 4 | May 16, 2023 | clinicaltrials |
| NCT05256277 | NK Cell Therapy for AML | terminated | Phase 1 | 3 | Zhejiang UniversityOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03233074 | Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors(COSMOS) | terminated | — | 93 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
| NCT04067180 | Randomized Clinical Study Assessing Haplo vs. URD in AML | terminated | N/A | 18 | Karolinska InstitutetOTHER | 5 | Apr 5, 2023 | clinicaltrials |
| NCT03878927 | CPX-351+GO in Subjects 55 Years Old, or Older, With AML(CPX GO) | terminated | Phase 1 | 11 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | terminated | Phase 3 | 52 | Goethe UniversityOTHER | 2 | Feb 16, 2023 | clinicaltrials |
| NCT02543749 | DC Vaccination in CML | terminated | Phase 1 / Phase 2 | 1 | Charite University, Berlin, GermanyOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) | terminated | Phase 1 | 22 | Magenta Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 43 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)(CATHY) | terminated | Phase 3 | 11 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT00573378 | Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia | terminated | Phase 2 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT00887926 | Study of IMC-EB10 in Participant With Leukemia | terminated | Phase 1 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | terminated | Phase 1 | 8 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04595851 | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications | terminated | N/A | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02448095 | Retrospective Evaluation of CML Patients in the National Compassionate Program | terminated | — | 38 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 26, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jan 31, 2024source: clinicaltrials